Characteristics of patients with DS AML and DS ALL
| . | DS AML . | DS ALL . |
|---|---|---|
| Number | 13 | 9 |
| Median age, y | 1.7 | 4.5 |
| Range | 0.0-2.5 | 0.0-15.4 |
| Sex, male:female | 7:6 | 5:4 |
| Median WBC, ×109/L | 18.6 | 22.3 |
| Range | 1.9-201.0 | 4.3-116.2 |
| FAB classification | ||
| M0 | 2 | — |
| M2 | 0 | — |
| M5 | 0 | — |
| M6 | 1 | — |
| M7 | 8 | — |
| TMD | 2 | — |
| Unclassified | 0 | — |
| Immunophenotype | B-cell precursor ALL | |
| n = 9 |
| . | DS AML . | DS ALL . |
|---|---|---|
| Number | 13 | 9 |
| Median age, y | 1.7 | 4.5 |
| Range | 0.0-2.5 | 0.0-15.4 |
| Sex, male:female | 7:6 | 5:4 |
| Median WBC, ×109/L | 18.6 | 22.3 |
| Range | 1.9-201.0 | 4.3-116.2 |
| FAB classification | ||
| M0 | 2 | — |
| M2 | 0 | — |
| M5 | 0 | — |
| M6 | 1 | — |
| M7 | 8 | — |
| TMD | 2 | — |
| Unclassified | 0 | — |
| Immunophenotype | B-cell precursor ALL | |
| n = 9 |
Data are shown only for patients with successful MTT assay.
TMD indicates transient myeloproliferative disease.